OPTIC NEUROPATHY IN PATIENTS WITH GLIOBLASTOMA RECEIVING BEVACIZUMAB

被引：37
|
作者：
Sherman, J. H. [2 ]
Aregawi, D. G.
Lai, A. [5 ]
Fathallah-Shaykh, H. M. [6 ]
Bierman, P. J. [7 ]
Linsky, K. [8 ]
Larner, J. M. [3 ]
Newman, S. A. [4 ]
Schiff, D. [1 ,2 ]
机构：
[1] Univ Virginia, Ctr Hlth Sci, Dept Neurol Surg, Charlottesville, VA 22908 USA
[2] Univ Virginia, Dept Neurol, Charlottesville, VA 22908 USA
[3] Univ Virginia, Dept Radiat Oncol, Charlottesville, VA 22908 USA
[4] Univ Virginia, Dept Ophthalmol, Charlottesville, VA 22908 USA
[5] Univ Calif Los Angeles, Med Ctr, Neurooncol Program, Los Angeles, CA 90024 USA
[6] Rush Univ, Div Neurosci, Sect Neurooncol, Chicago, IL 60612 USA
[7] Univ Nebraska, Dept Internal Med, Sect Oncol & Hematol, Omaha, NE 68182 USA
[8] Columbia Univ, Dept Med, New York, NY USA
来源：
NEUROLOGY | 2009年 / 73卷 / 22期
关键词：
CANCER;
D O I：
10.1212/WNL.0b013e3181c3fd00
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：1924 / 1926
页数：6
相关论文
共 50 条
  • [31] Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab
    Levin, Victor A.
    Chan, James
    Datta, Meenal
    Yee, Jennie L.
    Jain, Rakesh K.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2017, 134 (02) : 325 - 330
  • [32] Mutations for Leber hereditary optic neuropathy in patients with alcohol and tobacco optic neuropathy
    Amaral-Fernandes, Marcela Scabello
    Marcondes, Ana Maria
    do Amor Divino Miranda, Paulo Mauricio
    Maciel-Guerra, Andrea Trevas
    Sartorato, Edi Lucia
    [J]. MOLECULAR VISION, 2011, 17 (342-43): : 3175 - 3179
  • [33] Bevacizumab : is the lower the better for glioblastoma patients in progression?
    Sirven-Villaros, Lila
    Bourg, Veronique
    Mondot, Lydiane
    Fontaine, Denys
    Vandenbos, Fanny
    Frenay, Christine Lebrun
    [J]. NEUROLOGY, 2017, 88
  • [34] BEVACIZUMAB (BEV) IN ELDERLY PATIENTS WITH GLIOBLASTOMA (GBM)
    Welch, Mary R.
    Omuro, Antonio
    Grommes, Christian
    [J]. NEURO-ONCOLOGY, 2012, 14 : 82 - 82
  • [35] BEVACIZUMAB AND IRINOTECAN IN THE TREATMENT OF PATIENTS WITH RECURRENT GLIOBLASTOMA
    Naskhletashvili, D. R.
    Gorbounova, V.
    Bychkov, M.
    Bekyashev, A.
    Karakhan, V.
    Aloshin, V.
    Fu, R.
    Moskvina, E.
    [J]. NEURO-ONCOLOGY, 2012, 14 : 59 - 59
  • [36] ARTE and craft of bevacizumab in elderly patients with glioblastoma
    Schiff, D.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (06) : 1346 - 1347
  • [37] Bevacizumab: Is the lower the better for glioblastoma patients in progression?
    Sirven-Villaros, Lila
    Bourg, Veronique
    Suissa, Laurent
    Mondot, Lydiane
    Almairac, Fabien
    Fontaine, Denys
    Paquis, Philippe
    Burel-VandenBos, Fanny
    Frenay, Marc
    Thomas, Pierre
    Lebrun-Frenay, Christine
    [J]. BULLETIN DU CANCER, 2018, 105 (12) : 1135 - 1146
  • [38] Discontinuing Bevacizumab in Patients with Glioblastoma: An Ethical Analysis
    Kesselheim, Jennifer C.
    Norden, Andrew D.
    Wen, Patrick Y.
    Joffe, Steven
    [J]. ONCOLOGIST, 2011, 16 (10): : 1435 - 1439
  • [39] Bevacizumab residual concentration for recurrent glioblastoma patients
    Tabouret, E.
    Rousseau, B.
    Barrie, M.
    Thiebault, L.
    Chinot, O.
    Hulin, A.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2016, 30 : 26 - 26
  • [40] PROGNOSTIC VALUE OF [18F]-FDG POSITRON EMISSION TOMOGRAPHY IN PATIENTS WITH RECURRENT GLIOBLASTOMA RECEIVING BEVACIZUMAB
    Graham, Maya
    Krebs, Simone
    Bale, Tejus
    Domfe, Kwaku
    Lobaugh, Stephanie
    Zhang, Zhigang
    Dunphy, Mark
    Kaley, Thomas
    Young, Robert
    [J]. NEURO-ONCOLOGY, 2019, 21 : 177 - 178
12345